UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in Omnicell, Inc. (NASDAQ:OMCL) by 86.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 97,334 shares of the company’s stock after selling 643,292 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Omnicell were worth $4,244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in OMCL. PEAK6 Investments LLC bought a new stake in shares of Omnicell in the 3rd quarter valued at about $448,000. Millrace Asset Group Inc. bought a new stake in shares of Omnicell in the 3rd quarter valued at about $1,223,000. The Manufacturers Life Insurance Company raised its holdings in shares of Omnicell by 7.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 25,272 shares of the company’s stock valued at $1,102,000 after purchasing an additional 1,813 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Omnicell by 3.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 594,996 shares of the company’s stock valued at $25,942,000 after purchasing an additional 22,198 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Omnicell in the 3rd quarter valued at about $753,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

OMCL has been the subject of several recent research reports. Benchmark restated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. JPMorgan Chase & Co. boosted their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Craig Hallum boosted their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Wells Fargo & Company boosted their price objective on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Finally, Barclays boosted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $52.00.

Insiders Place Their Bets

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.64% of the stock is owned by insiders.

Omnicell Stock Down 2.2 %

NASDAQ OMCL opened at $45.96 on Friday. The firm has a market cap of $2.13 billion, a PE ratio of -117.85, a price-to-earnings-growth ratio of 34.95 and a beta of 0.77. The company has a 50 day moving average price of $45.25 and a 200 day moving average price of $38.90. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.